Dixon Hubard Feinour & Brown’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | $12.3M | Sell |
79,982
-1,752
| -2% | -$268K | 1.45% | 11 |
|
|
2022
Q1 | $13.3M | Sell |
81,734
-494
| -0.6% | -$71.8K | 1.33% | 18 |
|
|
2021
Q4 | $11.1M | Buy |
82,228
+4,174
| +5% | +$493K | 1.07% | 28 |
|
|
2021
Q3 | $8.42M | Buy |
78,054
+360
| +0.5% | +$41.1K | 1.79% | 18 |
|
|
2021
Q2 | $8.75M | Sell |
77,694
-75,788
| -49% | -$8.54M | 1.82% | 15 |
|
|
2021
Q1 | $15M | Buy |
153,482
+76,831
| +100% | +$8.22M | 1.85% | 15 |
|
|
2020
Q4 | $6.71M | Hold |
76,651
| – | – | 1.72% | 21 |
|
|
2020
Q3 | $6.71M | Buy |
76,651
+914
| +1% | +$86K | 1.72% | 21 |
|
|
2020
Q2 | $7.33M | Buy |
75,737
+69,032
| +1,030% | +$6.08M | 1.9% | 18 |
|
|
2020
Q1 | $511K | Buy |
6,705
+118
| +2% | +$10.1K | 0.17% | 97 |
|
|
2019
Q4 | $583K | Sell |
6,587
-300
| -4% | -$24.9K | 0.15% | 101 |
|
|
2019
Q3 | $521K | Sell |
6,887
-100
| -1% | -$6.86K | 0.14% | 106 |
|
|
2019
Q2 | $508K | Buy |
6,987
+374
| +6% | +$29.4K | 0.14% | 109 |
|
|
2019
Q1 | $533K | Buy |
6,613
+518
| +8% | +$42.4K | 0.16% | 103 |
|
|
2018
Q4 | $562K | Buy |
6,095
+200
| +3% | +$17.6K | 0.21% | 95 |
|
|
2018
Q3 | $558K | Hold |
5,895
| – | – | 0.15% | 107 |
|
|
2018
Q2 | $546K | Hold |
5,895
| – | – | 0.16% | 105 |
|
|
2018
Q1 | $558K | Sell |
5,895
-1,050
| -15% | -$115K | 0.16% | 106 |
|
|
2017
Q4 | $672K | Buy |
6,945
+100
| +1% | +$9.43K | 0.18% | 104 |
|
|
2017
Q3 | $608K | Buy |
6,845
+85
| +1% | +$6.47K | 0.17% | 108 |
|
|
2017
Q2 | $490K | Hold |
6,760
| – | – | 0.14% | 114 |
|
|
2017
Q1 | $440K | Sell |
6,760
-68,158
| -91% | -$4.29M | 0.13% | 118 |
|
|
2016
Q4 | $4.69M | Sell |
74,918
-1,513
| -2% | -$92.4K | 1.49% | 26 |
|
|
2016
Q3 | $4.82M | Buy |
76,431
+113
| +0.1% | +$7.32K | 1.5% | 23 |
|
|
2016
Q2 | $4.72M | Buy |
76,318
+925
| +1% | +$56.4K | 1.51% | 25 |
|
|
2016
Q1 | $4.6M | Sell |
75,393
-3,190
| -4% | -$178K | 1.5% | 25 |
|
|
2015
Q4 | $4.66M | Buy |
78,583
+877
| +1% | +$50.5K | 1.48% | 28 |
|
|
2015
Q3 | $4.23M | Buy |
77,706
+859
| +1% | +$55.9K | 1.56% | 24 |
|
|
2015
Q2 | $5.16M | Buy |
76,847
+1,231
| +2% | +$80.4K | 1.59% | 22 |
|
|
2015
Q1 | $4.43M | Buy |
75,616
+421
| +0.6% | +$25.4K | 1.31% | 30 |
|
|
2014
Q4 | $4.92M | Sell |
75,195
-258
| -0.3% | -$16.3K | 1.53% | 20 |
|
|
2014
Q3 | $4.36M | Buy |
75,453
+583
| +0.8% | +$32.4K | 1.43% | 26 |
|
|
2014
Q2 | $4.23M | Buy |
74,870
+1,025
| +1% | +$53.8K | 1.38% | 27 |
|
|
2014
Q1 | $3.8M | Buy |
73,845
+1,006
| +1% | +$50.8K | 1.32% | 29 |
|
|
2013
Q4 | $3.85M | Sell |
72,839
-1,325
| -2% | -$65.1K | 1.42% | 26 |
|
|
2013
Q3 | $3.32M | Buy |
74,164
+1,120
| +2% | +$49.6K | 1.41% | 27 |
|
|
2013
Q2 | $3.02M | Buy |
+73,044
| New | +$3.19M | 1.35% | 29 |
|
Other funds holding ABBV
Dixon Hubard Feinour & Brown's ABBV Position: Q2 2022 in Review
Dixon Hubard Feinour & Brown reduced its AbbVie (ABBV) stake by 2.1% in Q2 2022, selling an estimated $268K and leaving 79,982 shares worth $12.3M. The position accounts for 1.45% of the portfolio, ranked #11.
Dixon Hubard Feinour & Brown first reported a position in ABBV in Q2 2013 and has held it in 37 quarters since. The position peaked at $15M in Q1 2021. 3,004 funds tracked by Wall St. Rank hold ABBV as of Q2 2022.
- Dixon Hubard Feinour & Brown held 79,982 shares of AbbVie worth $12.3M as of Q2 2022.
- Dixon Hubard Feinour & Brown sold 1,752 AbbVie shares in Q2 2022, an estimated $268K.
- AbbVie made up 1.45% of Dixon Hubard Feinour & Brown's portfolio in Q2 2022, its #11 holding.
- Dixon Hubard Feinour & Brown first reported a position in AbbVie in Q2 2013 and has held it in 37 quarters since.
- Dixon Hubard Feinour & Brown's AbbVie position peaked at $15M in Q1 2021.
- 3,004 funds tracked by Wall St. Rank held AbbVie as of Q2 2022.
Based on Dixon Hubard Feinour & Brown's 13F filing for Q2 2022, filed 22 Jul 2022.